Role of Genetic Variations in the Hepatic Handling of Drugs

Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study

(2020) Luca Faloppi et al.   Targeted Oncology

Clinical Pharmacogenetics Implementation Consortium ( CPIC ) Guideline for CYP 2B6 and Efavirenz‐containing Antiretroviral Therapy

(2019) Zeruesenay Desta et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Causes of hOCT1‐Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor‐Selective Gene Therapy

(2019) Elisa Lozano et al.   HEPATOLOGY

Characterization of Plasma Membrane Localization and Phosphorylation Status of Organic Anion Transporting Polypeptide (OATP) 1B1 c.521 T>C Nonsynonymous Single-Nucleotide Polymorphism

(2019) Alexandra Crowe et al.   PHARMACEUTICAL RESEARCH

What “The Cancer Genome Atlas” database tells us about the role of ATP-binding cassette (ABC) proteins in chemoresistance to anticancer drugs

(2019) Oscar Briz et al.   Expert Opinion on Drug Metabolism & Toxicology

ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib

(2019) Giorgia Marisi et al.   Cancers

Multidrug resistance-associated protein 4 in pharmacology: Overview of its contribution to pharmacokinetics, pharmacodynamics and pharmacogenetics

(2019) Joseph Berthier et al.   LIFE SCIENCES

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study

(2019) Maeve A Lowery et al.   Lancet Gastroenterology & Hepatology

LBA10_PRClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation

(2019) G K Abou-Alfa et al.   ANNALS OF ONCOLOGY

LBA40FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)

(2019) A Vogel et al.   ANNALS OF ONCOLOGY

CYP3A5*3 and CYP2C8*3 variants influence exposure and clinical outcomes of tacrolimus-based therapy

(2019) Fabiana Dalla Vecchia Genvigir et al.   PHARMACOGENOMICS

The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool

(2018) Daniel F. B. Wright et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

(2018) Matthew P. Goetz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease

(2018) Tiago Furtado Sampaio et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance

(2018) Maciej J. Zamek-Gliszczynski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Epigenetic events involved in OCT1-dependent impaired response of hepatocellular carcinoma to sorafenib

(2018) Ruba Al-Abdulla et al.   BRITISH JOURNAL OF PHARMACOLOGY

Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine

(2018) Gaia Chiara Mannino et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure

(2018) Lauren A Marcath et al.   PHARMACOGENOMICS

A genetic variant in the catechol-O-methyl transferase (COMT) gene is related to age-dependent differences in the therapeutic effect of calcium-channel blockers

(2017) Jiayue Xu et al.   MEDICINE

PharmGKB summary

(2017) Alison E. Fohner et al.   Pharmacogenetics and Genomics

Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing

(2017) Yao Yang et al.   PHARMACOGENOMICS

Pharmacogenetics of oral antidiabetes drugs: evidence for diverse signals at the IRS1 locus

(2017) S Prudente et al.   PHARMACOGENOMICS JOURNAL

Identification of new SNPs associated with severe toxicity to capecitabine

(2017) Marta Pellicer et al.   PHARMACOLOGICAL RESEARCH

Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia

(2017) Whitney D. Maxwell et al.   PHARMACOTHERAPY

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH -Mutant Molecular Profiles

(2017) Farshad Farshidfar et al.   Cell Reports

CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes

(2016) Adem Y. Dawed et al.   DIABETES CARE

The Val158Met polymorphism in COMT gene and cancer risk: role of endogenous and exogenous catechols

(2016) Katrin Sak   DRUG METABOLISM REVIEWS

Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1α—Final results of the ALICE-2 study.

(2016) Luca Faloppi et al.   JOURNAL OF CLINICAL ONCOLOGY

Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients

(2016) Riccardo Giampieri et al.   Scientific Reports

HMGCR rs17671591 SNP Determines Lower Plasma LDL-C after Atorvastatin Therapy in Chilean Individuals

(2015) Alejandro Cuevas et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Organic Anion Transporting Polypeptide (OATP)1B1 and OATP1B3 as Important Regulators of the Pharmacokinetics of Substrate Drugs

(2015) Kazuya Maeda   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature

(2015) Stefan Wolking et al.   CLINICAL PHARMACOKINETICS

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines forCYP3A5Genotype and Tacrolimus Dosing

(2015) KA Birdwell et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Targeting the Δ133p53 isoform can restore chemosensitivity in 5-fluorouracil-resistant cholangiocarcinoma cells

(2015) NICHAPAVEE NUTTHASIRIKUL et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)

(2015) S. Bonora et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial

(2015) Jessica L Mega et al.   LANCET

ClinGen — The Clinical Genome Resource

(2015) Heidi L. Rehm et al.   NEW ENGLAND JOURNAL OF MEDICINE

PharmGKB summary

(2015) Maria L. Alvarellos et al.   Pharmacogenetics and Genomics

Variability in hepatic expression of organic anion transporter 7/SLC22A9, a novel pravastatin uptake transporter: impact of genetic and regulatory factors

(2015) A Emami Riedmaier et al.   PHARMACOGENOMICS JOURNAL

Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery

(2014) E Sim et al.   BRITISH JOURNAL OF PHARMACOLOGY

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

(2014) K R Crews et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Association of ABCB1 Polymorphisms With the Efficacy of Ondansetron in Chemotherapy-induced Nausea and Vomiting

(2014) Hui He et al.   CLINICAL THERAPEUTICS

The Pharmacogenetics of Type 2 Diabetes: A Systematic Review

(2014) Nisa M. Maruthur et al.   DIABETES CARE

VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study

(2014) Mario Scartozzi et al.   INTERNATIONAL JOURNAL OF CANCER

The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib

(2014) You-Bing Zheng et al.   MEDICAL ONCOLOGY

PharmGKB summary

(2014) Srijib Goswami et al.   Pharmacogenetics and Genomics

Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia

(2014) Nathalie K. Zgheib et al.   Pharmacogenetics and Genomics

Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies

(2014) Sujatha Suthandiram et al.   PHARMACOGENOMICS

N-acetyltransferase 1 polymorphism increases cotinine levels in Caucasian children exposed to secondhand smoke: the CCAAPS birth cohort

(2014) G K LeMasters et al.   PHARMACOGENOMICS JOURNAL

ATP-Binding Cassette Genes Genotype and Expression: A Potential Association with Pancreatic Cancer Development and Chemoresistance?

(2014) Li Pang et al.   Gastroenterology Research and Practice

Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care

(2013) Marianne K. DeGorter et al.   Circulation-Cardiovascular Genetics

International Transporter Consortium Commentary on Clinically Important Transporter Polymorphisms

(2013) K M Giacomini et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Expression ofSLC22A1variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib

(2013) Elisa Herraez et al.   HEPATOLOGY

Ratio disruption of the Δ133p53 and TAp53 isoform equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma

(2013) NICHAPAVEE NUTTHASIRIKUL et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

UGT1A1*6/*28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients

(2013) Jing Gao et al.   MEDICAL ONCOLOGY

The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARγ on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes

(2013) Tore B. Stage et al.   Pharmacogenetics and Genomics

PharmGKB summary

(2013) Christina L. Aquilante et al.   Pharmacogenetics and Genomics

Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line

(2013) Karin Skoglund et al.   Pharmacogenetics and Genomics

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

(2013) Ulrich M. Zanger et al.   PHARMACOLOGY & THERAPEUTICS

PHASE II DRUG METABOLIZING ENZYMES

(2012) Petra Jancova et al.   BIOMEDICAL PAPERS-OLOMOUC

Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults

(2012) Chonlaphat Sukasem et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacogenomics Knowledge for Personalized Medicine

(2012) M Whirl-Carrillo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

COMT as a Drug Target for Cognitive Functions and Dysfunctions

(2012) Diego Scheggia et al.   CNS & Neurological Disorders-Drug Targets

A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts

(2012) N. van Leeuwen et al.   DIABETOLOGIA

Influence of SLCO1B3 Genetic Variations on Tacrolimus Pharmacokinetics in Renal Transplant Recipients

(2012) Andrée-Anne Boivin et al.   Drug Metabolism and Pharmacokinetics

PharmGKB summary

(2012) Jatinder Lamba et al.   Pharmacogenetics and Genomics

Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients

(2012) Linda Tarasova et al.   Pharmacogenetics and Genomics

Predicting warfarin dosage in European–Americans and African–Americans using DNA samples linked to an electronic health record

(2012) Andrea H Ramirez et al.   PHARMACOGENOMICS

Dosing equation for tacrolimus using genetic variants and clinical factors

(2011) Chaitali Passey et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacogenetics: From Bench to Byte— An Update of Guidelines

(2011) J J Swen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy

(2011) S A Scott et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinically Relevant Genetic Variations in Drug Metabolizing Enzymes

(2011) Navin Pinto et al.   CURRENT DRUG METABOLISM

High Doses of Clopidogrel to Overcome Genetic Resistance

(2011) Jean-Philippe Collet et al.   JACC-Cardiovascular Interventions

Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations

(2011) H E Wheeler et al.   PHARMACOGENOMICS JOURNAL

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups

(2010) N. A. Limdi et al.   BLOOD

ABCG2 Polymorphism Is Associated With the Low-Density Lipoprotein Cholesterol Response to Rosuvastatin

(2010) B Tomlinson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical Implications of Pharmacogenetic Variation on the Effects of Statins

(2010) Simran D.S. Maggo et al.   DRUG SAFETY

Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese

(2010) P.-C. Cha et al.   HUMAN MOLECULAR GENETICS

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

(2010) Lokesh Jain et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Common polymorphisms of the peroxisome proliferator-activated receptor–γ (Pro12Ala) and peroxisome proliferator-activated receptor–γ coactivator–1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus

(2010) Ming-Chia Hsieh et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

PharmGKB summary: very important pharmacogene information for CYP2B6

(2010) Caroline F. Thorn et al.   Pharmacogenetics and Genomics

Cytochrome P450 2C9-CYP2C9

(2010) Derek Van Booven et al.   Pharmacogenetics and Genomics

Single nucleotide polymorphisms in genes that are associated with a modified response to statin therapy: the Rotterdam Study

(2010) C E de Keyser et al.   PHARMACOGENOMICS JOURNAL

The Role of Organic Anion–Transporting Polypeptides and Their Common Genetic Variants in Mycophenolic Acid Pharmacokinetics

(2009) N Picard et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin

(2009) J E Keskitalo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Ribavirin Analogs

(2009) William W. Shields et al.   Clinics in Liver Disease

Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding

(2009) Gerardo Blanco et al.   Pharmacogenetics and Genomics

Cytochrome P450 2D6

(2009) Ryan P. Owen et al.   Pharmacogenetics and Genomics

Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers

(2009) Jörn Lötsch et al.   Pharmacogenetics and Genomics

Common genetic variation in theABCB1gene is associated with the cholesterol-lowering effect of simvastatin in males

(2009) Matthijs L Becker et al.   PHARMACOGENOMICS

Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER

(2008) Eliana Polisecki et al.   ATHEROSCLEROSIS

Characterisation of novel defective thiopurine S-methyltransferase allelic variants

(2008) A. Garat et al.   BIOCHEMICAL PHARMACOLOGY

Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement

(2008) D. Wang et al.   BLOOD

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

(2008) G. M. Cooper et al.   BLOOD

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers

(2008) R. Michael Baldwin et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment

(2008) Corine Ekhart et al.   CANCER TREATMENT REVIEWS

Pharmacogenetic Predictors of Statin-Mediated Low-Density Lipoprotein Cholesterol Reduction and Dose Response

(2008) Deepak Voora et al.   Circulation-Cardiovascular Genetics

Different Effects ofSLCO1B1Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide

(2008) Annikka Kalliokoski et al.   JOURNAL OF CLINICAL PHARMACOLOGY

SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Changes in consensus arylamine N-acetyltransferase gene nomenclature

(2008) David W. Hein et al.   Pharmacogenetics and Genomics

Pharmacogenetics of Gilbert’s syndrome

(2008) Christian P Strassburg   PHARMACOGENOMICS